August Troendle Sells 673 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 673 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $620.38, for a total transaction of $417,515.74. Following the transaction, the chief executive officer directly owned 544,544 shares in the company, valued at approximately $337,824,206.72. This represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Medpace Stock Down 1.8%

Shares of NASDAQ:MEDP opened at $600.65 on Friday. The stock has a market cap of $16.76 billion, a PE ratio of 35.21, a PEG ratio of 2.73 and a beta of 1.15. The company’s fifty day moving average is $565.33 and its 200 day moving average is $494.55. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the business posted $3.10 earnings per share. The company’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MEDP shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Royal Bank Of Canada raised their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $584.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the second quarter valued at approximately $27,000. Elyxium Wealth LLC bought a new position in Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new position in Medpace during the second quarter valued at $30,000. Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter valued at $31,000. Finally, Kilter Group LLC bought a new stake in shares of Medpace during the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.